# Supernus (SUPN) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/SUPN
## Company Profile
- Ticker: SUPN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 46.91 USD
- Market cap: 2557810504.47 USD
- Last updated: 2026-08-05
## Business Overview
### CNS Commercial Portfolio
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea.
### Growth Products
The company’s principal growth brands include Qelbree for ADHD, GOCOVRI for dyskinesia in Parkinson’s disease, ONAPGO for continuous treatment of motor fluctuations in Parkinson’s disease and ZURZUVAE for postpartum depression. ZURZUVAE is commercialized through an economic collaboration with Biogen.
### Epilepsy and Depression Pipeline
SPN-817 is a selective acetylcholinesterase inhibitor in a Phase 2b trial for treatment-resistant focal seizures. SPN-820 is designed to increase mTORC1-mediated synaptic function and is in Phase 2b development as an adjunctive treatment for major depressive disorder.
### ADHD Pipeline Expansion
SPN-443 is a novel stimulant candidate for ADHD. Its planned first-in-human study extends Supernus’s pipeline within a therapeutic area where the company already has commercial infrastructure through Qelbree.
## Why The Stock Is Moving

As of Aug 5, 2026, SUPN closed up 8.46% at $46.91. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 1 initiation for SPN-443 expected in the second half of 2026.
- FDA submission for a second ONAPGO supplier expected in the third quarter of 2026, with potential approval by mid-2027.

## Recent News
- 2026-08-03 10:35 EST — [Supernus Announces Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/SUPN/supernus-announces-second-quarter-2026-financial-results-5dc034a4) — Source: Supernus
- 2026-08-03 10:30 EST — [Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-and-indivior-pharmaceuticals-to-merge-creating-a-divers-3b4a29fd) — Source: Supernus
- 2026-07-22 21:05 EST — [Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2026-financial-results-and-h-58b4f63d) — Source: Supernus
- 2026-07-14 12:30 EST — [Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD](https://biopharmsignal.com/news/SUPN/supernus-celebrates-five-year-anniversary-of-qelbree-fda-approval-continuing-to--ca53fc4f) — Source: Supernus
- 2026-05-27 20:30 EST — [Supernus Pharmaceuticals to Participate in June Investor Conferences](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-participate-in-june-investor-conferences) — Source: Supernus